Title: Sirtris Pharmeceuticals CEO Christoph Westphal

" Next -- the latest news on getting old specifically an update on the development of drugs that target enzymes associated with aging and age related illnesses. Cambridge Massachusetts company pioneering the science here doctor Christoph Westphal is CEO of -- Chris. Pharmaceuticals -- welcome back good to see if it's great to be back we have told the story sixty minutes has told this story it's about a substance called -- very patrol found in red -- quick review."

" exactly so RD if you ate less food or if you took a lot of prisoner troll you would live longer at least if you are a lab rat."

" We've shown in animal studies that you can lower glucose and insulin and you can live a longer healthier life. Now we've taken into humans and John in diabetics you can also lower insulin."

" to those trials and a second but let me stick with us or there's not a lot of this in Vietnam War do you have to have been consumed a lot of the so what you've done. Is you chemically formulated that come."

" I exactly so we are a drug discovery and development company were developing this as a drug to treat diabetes and other diseases of aging."

" SRT 50 what is what we're talking about SRT 501 and then we have much more powerful molecules is on the clinic."

" And 501 is in the face to it -- sort of the mid stage of the FDA trial process where who who's trying this out where the testing conducted."

" so we've actually already seen and hundreds of diabetics that you can lower glucose and you can also lower insulin which is exactly what you wanna do diabetics. We've also taken molecules that are about a thousand times more of the reserve trawl. Move them into several phase one studies and are now in phase two studies in diabetes as well this is what -- NC east new chemical entities exactly help us with the definition I'm so these are synthetic molecules they don't look chemically like prisoner troll but they have the same activity -- just. Thousand times more potent and the targets here are diabetes as you said cancer. Neurological diseases as well really all the diseases of aging and in the very interesting thing for riot if we're targeting the genes that control the aging process we should be able to treat and cure a lot of the major killers of western society since we last talked you've been book. Yeah we we were very fortunate we were publicly traded did well as a public company in the last June we were acquired our first it was a slam dunk. We got very fortunate yeah. And GlaxoSmithKline. -- about it for 720. Million dollars. Exactly and that it looks like it's gonna be very good deal for them as well if any of our disease. If any of our studies working any of these diseases were talking about this can be a very significant drug for --"

" That edit and the pattern that we're seeing now in the drug industry it costs a lot to bring a drug to market through that lengthy period. A lot of upfront about it big burn rate venture capital and whatever money you're able to race on IPOs. These alliances these mergers and acquisitions -- what we're seeing more and more pharmaceutical industry."

" Yeah well now I'm part of GlaxoSmithKline. And I actually helped to run their external investing and and and really a lot of innovation is found in places like Boston so these big companies really look for the breakthrough science and the new medicines in small Biotech."

" Let me turn the -- to health care reform we talk a lot in this debate about controlling the cost of health -- bringing down that bill that is about what sixth of the gross domestic product out here. In this country. What role do drugs play in making that happen to the target here if it's diving it is if you do something about controlling that -- got the bill yet."

" One of the great things for search Chris is that if we're actually right about our science we're talking about increasing healthy lifespan. So we're talking about. Reducing diseases of aging that's really one of the most cost effective ways. To impact. You know the overall expense for society of health care."

" You can go from euphoria to disappointment pretty quickly if your business what are we have definitive results from the clinical trials here that are involved."

" With a great news is that we have multiple phase two studies efficacy studies so I'd say the odds of this working and at least one of them are quite high and then the question is when might we reach the market -- Alice Carlson into the drugs available. We think conservatively somewhere between four and six years from now assuming things go well. All right there you go and update from circus pharmaceuticals Christoph Westphal co-founder and CEO of certain respects -- security."